Death of the Blockbuster Drug

By Paul Kedrosky · Friday, March 30, 2007 ·
The current NEJM has a good piece on the death of the blockbuster drug. The threefold argument:
  1. It is ever-rarer for one drug to be the only one in its class. The average new drug in the 1970s enjoyed 10.2-years of market exclusivity, while that is now down to 1.2 years.
  2. Even with healthcare, not everyone can afford all prescription medications
  3. The blockbuster model relies on the proposition that one drug size fits all, which is less true than ever
Provocative stuff.
1